CJC-1295 with DAC 5mg

CJC-1295 (With DAC) (5mg) — Research Compound

CJC-1295 (With DAC) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) that incorporates a Drug Affinity Complex (DAC). This modification allows the peptide to bind covalently to circulating albumin, significantly extending its half-life to several days. It is primarily studied for its ability to provide continuous stimulation of the pituitary gland, resulting in sustained elevations of growth hormone and IGF-1 levels rather than the pulsatile release seen with shorter-acting secretagogues.

Findings from early-stage clinical trials have reported:

• Mean increases in plasma growth hormone levels of up to 10-fold observed for over a week following a single dose
  
• Sustained elevations in serum IGF-1 concentrations reported in healthy research participants
  
• Improvements in body composition, including reduced fat mass, noted in experimental models
  
• Enhanced cellular repair and protein synthesis markers observed during prolonged study periods
  

Researchers study CJC-1295 (With DAC) to investigate the biological effects of chronic versus pulsatile growth hormone elevation. The inclusion of the DAC component makes it a unique tool for understanding how long-term hormonal signalling affects systemic metabolism and tissue homeostasis. Its extended activity profile allows for research into the efficiency of less frequent administration protocols in maintaining elevated somatotropic activity.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use